High Cost/Low Use Drugs: Risks and Opportunities for Medicaid MCOs
High-cost, low-utilization (HCLU) drugs represent a critical concern for Medicaid plans. While these drugs account for a relatively small proportion of prescriptions, their disproportionate impact on health plan expenditures can destabilize budgets and complicate capitation rate-setting.
CuraFi and ACAP are now recruiting a small group of ACAP member plans to
